Authors
Latest:
CLL in the Era of Targeted TherapiesOver the past few years, remarkable advances have been achieved in the field of CLL by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival. These developments have been achieved by a better understanding of the underlying biology and the disease process.
Latest:
Treatment Sequencing in Metastatic Colorectal CancerAn expert breaks down therapy sequencing in metastatic colorectal cancer and provides some clinical pearls.
Latest:
Takeaways From Lung-MAP Substudy S1800A in NSCLCKaren L. Reckamp, MD, MS, discusses findings from the phase 2 Lung-MAP substudy S1800A of pembrolizumab and ramucirumab in patients with stage IV, previously-treated non–small cell lung cancer.
Latest:
Toxicities Associated With Talazoparib/Enzalutamide in HRR-Mutant mCRPCKarim Fizazi, MD, discusses the toxicities seen with the combination of talazoparib plus enzalutamide.
Latest:
Sequencing Immunotherapy and Targeted Therapy in MelanomaKarl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing immunotherapy and targeted therapy for patients with melanoma.
Latest:
Evaluating the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCLKarl M. Kilgore, PhD, discusses the role of chimeric antigen receptor T-cell therapy as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and where this option might fit into the landscape in the future.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot StudyAlthough there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Latest:
Geospatial and Temporal Analysis Show Increased Thyroid Cancer Incidence in Rural PopulationThe incidence of thyroid cancer, which is now the most rapidly increasing endocrine malignancy, has been increasing at a rate of 3% to 5% per year, resulting in a near doubling in the past 30 years.
Latest:
Programs Prepare for Immuno-Oncology in Clinical SettingClinicians will soon face challenging decisions on which immunotherapies to prescribe their patients, and in what sequence or combination.
Latest:
Decision Making and Patient Preferences Prior to SurgeryKatharine Yao, MD, gives an overview of an analysis that looked at patient preferences prior to surgery.
Latest:
Dr. Katherine Van Loon on Recognizing Recurrences in Gastrointestinal CancersVan Loon says that oncologists need further research into how often and for how long patients with gastrointestinal cancers should be monitored.
Latest:
Safety Findings of Long-Term Bevacizumab for Patients with Ovarian CancerKathleen Essel, MD, a fellow at University of Oklahoma Health Science Center, discusses the findings from a recent trial investigating the safety of long-term treatment with bevacizumab in patients with ovarian cancer.
Latest:
Evaluating the Role of Quantitative Computed Tomography Image Feature Analysis in Gynecologic CancersKathleen G. Essel, MD, discusses the role of quantitative imaging feature analysis in gynecologic cancers.
Latest:
Mirvetuximab Soravtansine Remains Well Tolerated in Platinum-Resistant Ovarian CancerKathleen Moore, MD, discusses the findings from the phase III FORWARD-1 trial that investigated mirvetuximab soravtansine in women with folate receptor alpha–positive platinum-resistant ovarian cancer. These findings were presented at the 2019 ESMO Congress.
Latest:
Challenges With PARP Inhibitors in Ovarian CancerKathleen N. Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discusses challenges with PARP inhibitors in ovarian cancer.
Latest:
Surgeons' Association Calls for Change in National Breast Cancer GuidelinesIt is rare that treatment guidelines make sweeping changes to treatment recommendations, yet the American Society of Breast Surgeons is urging that the National Comprehensive Cancer Network guidelines on breast cancer treatment be changed to indicate that genetic testing be offered to all patients with breast cancer.
Latest:
A Study Examining Brentuximab Vedotin in Patients With High-Risk Large B-Cell LymphomaKathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).<br />
Latest:
Durvalumab Demonstrates Durable Responses in Recurrent GBMFindings from a recent phase II study showed the PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme (GBM).
Latest:
Staging versus Biology in Breast CancerKathy S. Albain, MD, discusses staging versus biology in breast cancer.
Latest:
Immunotherapy Offers a Cutting-Edge BoostEvolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.
Latest:
Osimertinib Improves Survival in EGFR+ NSCLC, Poses New Challenges for ResistanceKazuhiko Nakagawa, MD, PhD, discusses the role of EGFR tyrosine kinase inhibitors for the frontline treatment of patients with <em>EGFR</em>-positive non–small cell lung cancer.
Latest:
The Role of Neoadjuvant Chemoimmunotherapy in Stage I TNBCKeerthi Gogineni, MD, MSHP, discusses the use of preoperative chemoimmunotherapy in patients with stage I triple negative breast cancer.
